Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. MESO
MESO logo

MESO Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Mesoblast Ltd (MESO) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Sell
Latest Price
13.760
1 Day change
-1.22%
52 Week Range
21.500
Analysis Updated At
2026/06/12
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

MESO is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is in a weak technical position, has no recent positive news catalyst, no strong proprietary buy signal, and the options market is showing extremely bullish call-heavy activity that looks more like short-term speculation than a clean long-term entry. Given the current setup, the better decision is to avoid buying now.

Technical Analysis

The chart setup is bearish. MACD histogram is negative at -0.071 and still contracting, RSI_6 is neutral at 44.514, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Price is trading around 14.01, below the pivot at 14.556 and only slightly above support at 13.849, which leaves limited upside unless it reclaims resistance. The provided stock trend estimate also points lower over the short term, with a 70% chance of a decline in the next day, week, and month. Overall, momentum remains weak.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Options sentiment is heavily call-skewed, which suggests strong bullish speculation in the options market. However, implied volatility is extremely elevated at 304.14 with IV percentile at 100 and IV rank at 147.93, meaning option prices are very expensive. Open interest and volume both show very low put-call ratios, but this looks more like aggressive short-term positioning than a reliable long-term buy signal. The options data is bullish on sentiment, but not attractive for a beginner long-term investor.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
3

Positive Catalysts

  • ["Options flow is strongly call-biased, indicating speculative bullish sentiment.", "Pre-market price is holding near 14.01, slightly above the key support zone.", "No major negative news was reported in the past week."]

Neutral/Negative Catalysts

  • ["No news in the recent week, so there is no fresh catalyst supporting the stock.", "Technical trend is bearish across MACD, RSI, and moving averages.", "Short-term modeled price trend points downward.", "Hedge funds and insiders are neutral, showing no meaningful accumulation signal.", "No recent congress trading activity was reported.", "Implied volatility is extremely high, which makes options expensive and often reflects uncertainty rather than stable upside."]

Financial Performance

No usable latest-quarter financial snapshot was provided because the data returned an error, so I cannot assess revenue or earnings growth for the most recent quarter. As a result, there is no financial growth confirmation available for long-term conviction.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target trend data was provided in the dataset, so there is no evidence here of improving Wall Street coverage. Based on the available information, the Wall Street pros and cons view is tilted negative: the pros are a bullish options tone and no recent bad news, while the cons are weak technicals, no insider or hedge fund support, no catalyst, and no financial update to justify a long-term buy.

Wall Street analysts forecast MESO stock price to rise
1 Analyst Rating
Wall Street analysts forecast MESO stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.760
sliders
Low
35
Averages
35
High
35
Current: 13.760
sliders
Low
35
Averages
35
High
35
Jefferies
Hold
to
Buy
upgrade
$3
AI Analysis
2025-11-25
Reason
Jefferies
Price Target
$3
AI Analysis
2025-11-25
upgrade
Hold
to
Buy
Reason
Jefferies upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3.
Jefferies
David Stanton
Hold
to
Buy
upgrade
$3
2025-11-25
Reason
Jefferies
David Stanton
Price Target
$3
2025-11-25
upgrade
Hold
to
Buy
Reason
As previously reported, Jefferies analyst David Stanton upgraded Mesoblast to Buy from Hold with a price target of A$3.30, up from A$3. Ryoncil continues to be rolled out and the firm forecasts 78 patients will complete therapy in FY26, up from 63, while updating its estimates for fiscal Q2 results and FY26 forecasts.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for MESO
Unlock Now

People Also Watch